FilingsTodayAbbott Laboratories
At a glance
Abbott Laboratories reported 2025 revenue of $44.33B, up 5.7% from $41.95B in 2024. Over 4 years since 2021 ($43.08B), that is growth of about 0.7% a year. Operating margin was 18.2%, down from 19.6% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 10 insiders reported 5 open-market purchases ($4.4M) and 10 sales ($47.5M). None of the sales were flagged as 10b5-1 plan trades. The largest was a sale of $46.2M by CHAIRMAN AND CEO Robert B Ford on Aug 27, 2026. Net, insiders were sellers of $43.1M.
Abbott Laboratories filed 15 current reports (Form 8-K) in the last 12 months, most often for other events (4), results of operations (4), bylaws or fiscal year change (3) and material agreement (3). The latest officer or director change was reported on Apr 27, 2026. It reported a material agreement or a completed acquisition or disposal 3 times.
4 of the 20 investors tracked here held Abbott Laboratories at the last quarter end, worth $453.6M combined. It is the largest weight for National Pension Service (Korea) (0.2% of its portfolio), followed by Renaissance Technologies (0.1%). Added: National Pension Service (Korea). Reduced: Renaissance Technologies and Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $7.07B | $6.93B | $5.72B | $13.4B | $6.52B |
| Diluted EPS | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Dividend per share | - | $1.92 | $2.08 | $2.24 | $2.40 |
Fiscal year ends Dec 31 · incorporated in IL
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined